Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...

Eli Lilly is reported to be eyeing a $1 billion-plus takeover of Ventyx Biosciences that, if confirmed, suggests 2026 could ...

For pharmaceutical marketers, the pharmacy relationship is as powerful as it is underutilised. Rather than focusing outreach ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

Meanwhile, NICE also published new guidance supporting NHS use of an AI-based automated tool, ArtiQ's ArtiQ.Spiro, which ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be ...

To reach HCPs, don’t try to be everywhere. Just be where they are. “Omnichannel” – the marketing strategy buzzword that has ...

Tickets are on sale for the 40th anniversary of the PM Awards! Book now and join the PM Society on Friday, 20th March 2026 at ...

Dr Schüttrumpf also discusses emerging platforms such as recombinant polyclonal therapeutics, as well as the integration of ...

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...

Lilly has seen dramatic sales growth over the last couple of years from its injectable, dual GLP-1/GIP agonist obesity ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...